Skip to main content
. 2020 Aug 26;5(4):e000714. doi: 10.1136/esmoopen-2020-000714

Figure 2.

Figure 2

OS (A) and PFS (B) based on duration of prior sorafenib. OS, overall survival; PFS, progression-free survival.